新冠神药大战：除了默沙东，四季度还有3家3期临床揭盲

华尔街见闻2021-10-02

在默沙东公布积极临床数据后，新冠口服药成为市场关注焦点。除了默沙东外，四季度还有3家公司将公布其新冠口服药3期临床数据，这其中包括来自中国的开拓药业。能够降低50%住院或死亡风险美东时间10月1日周五，老牌制药巨头公司默沙东率先传来好消息，其与合作伙伴Ridgeback生物治疗公司共同开发的口服抗新冠病毒试验性药丸，能够降低50%住院或死亡风险。默沙东公司称，该中期试验跟踪了775名患有轻度...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

Youn7276
2021-10-04
Youn7276
阅
RomySKT
2021-10-03
RomySKT
[微笑]
- RomySKT:
  [微笑]
Fattkhong
2021-10-03
Fattkhong
看看还有谁
- Fattkhong:
  [财迷]
小虎和小孩
2021-10-03
小虎和小孩
期待！感谢科学家们
Ohaiyo
2021-10-02
Ohaiyo
可以啊
CalvinChong
2021-10-02
CalvinChong
好的

发表看法

131

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2172969741?lang=zh_CN&edition=full","thumbnail":"https://static.tigerbbs.com/5caed408891c5ae9176e1a31289a0785","is_english":false,"pubTime":"2021-10-02 09:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2172969741","market":"us","top_or_hot":-1,"title":"新冠神药大战：除了默沙东，四季度还有3家3期临床揭盲","media":"华尔街见闻","content":"<div>\n<p>在默沙东公布积极临床数据后，新冠口服药成为市场关注焦点。除了默沙东外，四季度还有3家公司将公布其新冠口服药3期临床数据，这其中包括来自中国的开拓药业。\n能够降低50%住院或死亡风险\n美东时间10月1日周五，老牌制药巨头公司默沙东率先传来好消息，其与合作伙伴Ridgeback生物治疗公司共同开发的口服抗新冠病毒试验性药丸，能够降低50%住院或死亡风险。\n默沙东公司称，该中期试验跟踪了775名患有轻度...</p>\n\n<a href=\"https://wallstreetcn.com/articles/3641648\">网页链接</a>\n\n</div>\n","source":"wallstreetcn_api","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>新冠神药大战：除了默沙东，四季度还有3家3期临床揭盲</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n新冠神药大战：除了默沙东，四季度还有3家3期临床揭盲\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-02 09:18 北京时间&nbsp;&nbsp;&nbsp;<a href=https://wallstreetcn.com/articles/3641648><strong>华尔街见闻</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>在默沙东公布积极临床数据后，新冠口服药成为市场关注焦点。除了默沙东外，四季度还有3家公司将公布其新冠口服药3期临床数据，这其中包括来自中国的开拓药业。\n能够降低50%住院或死亡风险\n美东时间10月1日周五，老牌制药巨头公司默沙东率先传来好消息，其与合作伙伴Ridgeback生物治疗公司共同开发的口服抗新冠病毒试验性药丸，能够降低50%住院或死亡风险。\n默沙东公司称，该中期试验跟踪了775名患有轻度...</p>\n\n<a href=\"https://wallstreetcn.com/articles/3641648\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRK","symbol_name":"默沙东","start_time":0,"source_url":"https://wallstreetcn.com/articles/3641648","article_id":"2172969741","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/5caed408891c5ae9176e1a31289a0785"],"rights":{"source":"wallstreetcn_api","url":"https://wallstreetcn.com/articles/3641648","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2172969741","pubTimestamp":1633137514,"sourceInfo":{"source_id":"wallstreetcn_api","name":"华尔街见闻"},"weMediaInfo":null,"summary":"辉瑞、罗氏及来自中国的开拓药业预计将在四季度公布其新冠口服药3期临床数据。","collect":0,"end_time":0,"defaultTopTitle":"wallstreetcn.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"MRK":"默沙东"},"translate_title":"COVID-19 God Medicine War: In addition to Merck, there are 3 Phase 3 clinical blindness in the fourth quarter","themeId":null,"isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/cc9c6adbba13ce6c8d310c5d980df54d","symbols_score_info":{"MRK":0.9},"content_text":"在默沙东公布积极临床数据后，新冠口服药成为市场关注焦点。除了默沙东外，四季度还有3家公司将公布其新冠口服药3期临床数据，这其中包括来自中国的开拓药业。\n能够降低50%住院或死亡风险\n美东时间10月1日周五，老牌制药巨头公司默沙东率先传来好消息，其与合作伙伴Ridgeback生物治疗公司共同开发的口服抗新冠病毒试验性药丸，能够降低50%住院或死亡风险。\n默沙东公司称，该中期试验跟踪了775名患有轻度至中度新冠的成年人。试验结果显示，在新冠症状出现5天内，服用抗病毒口服药丸molnupiravir的患者中，仅7.3%的人在30天后住院或死亡，而服用安慰剂的患者中，这一比例为14.1%。\n沙东公司称，目前正计划尽快向FDA提交治疗紧急使用授权的申请，并将向世界各地的其他卫生监管机构寻求紧急使用授权。\n据相关专业媒体整理，此次公布的数据：Molnupiravir治疗组的住院或死亡率为7.3%（28/385），对照组的住院或死亡率为14.1%（53/377），Molnupiravir降低住院或死亡率50%，p值为0.0012。死亡率方面，治疗组没有死亡，对照组有8例死亡。\n作为小分子抗病毒药物，Molnupiravir的临床疗效可谓非常显著，虽然住院/死亡率降低幅度仍低于中和抗体，但治疗组没有死亡也说明治疗效果非常显著。小分子药物也具有显著的成本优势，生产规模容易放大。\n截止收盘，道指成份股默沙东（MRK）盘中涨幅一度超过12%，收于81.4美元，创2009年以来的最高盘中涨幅。与之相对，而新冠疫苗开发商则曾集体下跌态势，其中CureVac收跌逾14.7%，诺瓦瓦克斯跌12.4%，莫德纳跌约11.4%，Vaxart跌约9.7%，BioNTech跌约6.7%，INO跌超6.4%。\n\n四季度还有3家3期临床揭盲\n默沙东的亮眼数据使得新冠口服药成为市场焦点。\n华尔街见闻·见智研究所此前统计显示，四季度全球还有3家公司将公布其新冠口服药3期临床数据，包括开拓药业的AR拮抗剂普克鲁胺(III期)，罗氏的RNA聚合酶抑制剂AT-527(III期)，辉瑞的3CL蛋白酶抑制剂PF-07321332(III期)。其中来自中国的开拓药业最受中国投资者关注。\n普克鲁胺是开拓药业研发的一款AR(雄激素受体androgenreceptor)拮抗剂。据开拓药业相关研究，普克鲁胺通过抑制雄激素受体功能，从转录水平下调ACE2和TMPRSS2的表达，进而阻断SARS-CoV-2进入宿主细胞。\n开拓药业此前于9月1日午间公告称，公司已获得国家药品监督管理局批准，于中国进行普克鲁胺片拟用于治疗新型冠状病毒肺炎的针对轻中症和住院重症患者两项3期临床试验。这也是第一个在中国大陆开展3期临床的新冠口服药。\n华尔街见闻·见智研究所认为，开拓的普克鲁胺在新冠轻中重症上都有治疗潜力。此外，普克鲁胺在重症患者上的疗效可能与目前尚未发现的机制有关，比如对炎症风暴的作用还未有研究结论公布。\n需要注意的是，从小规模的前期数据上看，几款口服药普遍对不用住院的轻中症患者有明显效果，能够阻断病毒感染或复制，快速降低病毒载量，大幅降低患者症状转重的可能。\n但药物对于住院的重症患者，大部分通过抑制病毒复制原理的药物则效果不是特别好，因为重症患者本身多有细胞因子风暴等其他病征，单纯抑制病毒对这些症状很难起到逆转作用。","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":867599098,"gmtCreate":1633296233628,"gmtModify":1633296323971,"author":{"id":"3577393549070429","authorId":"3577393549070429","name":"Youn7276","avatar":"https://static.tigerbbs.com/487c5c26a5e210d6b88adaeaba12329b","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"阅","listText":"阅","text":"阅","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/867599098","repostId":2172969741,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":867818092,"gmtCreate":1633236092546,"gmtModify":1633236092708,"author":{"id":"3579783453007050","authorId":"3579783453007050","name":"RomySKT","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"[微笑]&nbsp;","listText":"[微笑]&nbsp;","text":"[微笑]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/867818092","repostId":2172969741,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6076487,"gmtCreate":1633236101827,"gmtModify":1634723365865,"authorId":3579783453007050,"author":{"id":3579783453007050,"authorId":3579783453007050,"name":"RomySKT","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":867818092,"type":1,"supId":0,"prevId":0,"content":"[微笑]","text":"[微笑]","html":"[微笑]"}],"langContent":"CN"},{"id":867831030,"gmtCreate":1633234824135,"gmtModify":1633234824226,"author":{"id":"3576924513004067","authorId":"3576924513004067","name":"Fattkhong","avatar":"https://static.tigerbbs.com/103cabc985ecc134ed2de3f8a949d852","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"看看还有谁","listText":"看看还有谁","text":"看看还有谁","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/867831030","repostId":2172969741,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6076331,"gmtCreate":1633234832706,"gmtModify":1634723379279,"authorId":3576924513004067,"author":{"id":3576924513004067,"authorId":3576924513004067,"name":"Fattkhong","avatar":"https://static.tigerbbs.com/103cabc985ecc134ed2de3f8a949d852","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":867831030,"type":1,"supId":0,"prevId":0,"content":"[财迷]","text":"[财迷]","html":"[财迷]"}],"langContent":"CN"},{"id":867368013,"gmtCreate":1633218262692,"gmtModify":1633218263179,"author":{"id":"3582713177188935","authorId":"3582713177188935","name":"小虎和小孩","avatar":"https://static.tigerbbs.com/059621c51ba25b6a865b0278e6b8b9cb","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"期待！感谢科学家们","listText":"期待！感谢科学家们","text":"期待！感谢科学家们","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/867368013","repostId":2172969741,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":867938041,"gmtCreate":1633183331952,"gmtModify":1633183332088,"author":{"id":"3578559537142791","authorId":"3578559537142791","name":"Ohaiyo","avatar":"https://static.tigerbbs.com/7df1a4d20064fd67209054f6e5bbc518","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"可以啊","listText":"可以啊","text":"可以啊","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/867938041","repostId":2172969741,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":867055870,"gmtCreate":1633173841739,"gmtModify":1633173841932,"author":{"id":"3573814781456643","authorId":"3573814781456643","name":"CalvinChong","avatar":"https://static.tigerbbs.com/a70af8809a95756364cc82fcfde2f404","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"好的","listText":"好的","text":"好的","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/867055870","repostId":2172969741,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":131,"commentSize":11,"repostSize":0,"favoriteSize":1,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.0","shortVersion":"4.25.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2172969741"}